Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
暂无分享,去创建一个
[1] D. Giugliano,et al. Intensive Lifestyle Intervention for Type 2 Diabetes. , 2017, JAMA.
[2] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.
[3] B. Zinman,et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.
[4] S. Solomon,et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.
[5] C. Cannon,et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes , 2015, Diabetes, obesity & metabolism.
[6] R. DeFronzo,et al. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. , 2015, European heart journal.
[7] E. Ferrannini,et al. Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition , 2015, Diabetes Care.
[8] M. Pencina,et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.
[9] Daniel F. Freitag,et al. Association of Cardiometabolic Multimorbidity With Mortality. , 2015, JAMA.
[10] E. S. Onge,et al. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes. , 2015, Clinical therapeutics.
[11] S. Solomon,et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. , 2015, American heart journal.
[12] F. Pattou,et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion , 2015, Nature Medicine.
[13] B. Zinman,et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials , 2015, Diabetes & vascular disease research.
[14] P. Narendran,et al. Dapagliflozin for the treatment of type 2 diabetes: a review of the literature , 2014, Drug design, development and therapy.
[15] T. Heise,et al. Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus , 2014, Diabetes, obesity & metabolism.
[16] U. Broedl,et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. , 2014, Kidney international.
[17] Deepak L. Bhatt,et al. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial , 2014, Circulation.
[18] Yu Hasegawa,et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice , 2014, Cardiovascular Diabetology.
[19] M. Nauck. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes , 2014, Drug design, development and therapy.
[20] M. Ridderstråle,et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. , 2014, The lancet. Diabetes & endocrinology.
[21] J. Yatabe,et al. Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy. , 2014, Journal of diabetes and its complications.
[22] T. Abraham,et al. Inhibiting Mitochondrial Na+/Ca2+ Exchange Prevents Sudden Death in a Guinea Pig Model of Heart Failure , 2014, Circulation research.
[23] B. Zinman,et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) , 2014, Cardiovascular Diabetology.
[24] A. Sinclair,et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies , 2014, BMC Endocrine Disorders.
[25] W. White,et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. , 2014, Journal of the American Society of Hypertension : JASH.
[26] U. Broedl,et al. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.
[27] R. DeFronzo,et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. , 2014, The Journal of clinical investigation.
[28] T. Heise,et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. , 2014, The Journal of clinical investigation.
[29] J. Bolinder,et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin , 2014, Diabetes, obesity & metabolism.
[30] U. Broedl,et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus , 2014, Cardiovascular Diabetology.
[31] H. Koepsell,et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. , 2014, American journal of physiology. Renal physiology.
[32] M. Monami,et al. Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trials , 2014, Diabetes, obesity & metabolism.
[33] Desmond E. Williams,et al. Changes in diabetes-related complications in the United States. , 2014, The New England journal of medicine.
[34] Craig Wilson,et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.
[35] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[36] Lawrence A Leiter,et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial , 2013, The Lancet.
[37] R. DeFronzo,et al. Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes , 2013, Diabetes Care.
[38] M. Sasamata,et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. , 2013, European journal of pharmacology.
[39] D. de Zeeuw,et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes , 2013, Diabetes, obesity & metabolism.
[40] É. Hardy,et al. Effects of Dapagliflozin on Cardiovascular Risk Factors , 2013, Postgraduate medicine.
[41] A. Wilde,et al. Late Sodium Current Inhibition in Acquired and Inherited Ventricular (dys)function and Arrhythmias , 2013, Cardiovascular Drugs and Therapy.
[42] C. Clar,et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes , 2012, BMJ Open.
[43] E. Ferrannini,et al. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects , 2012, Nature Reviews Endocrinology.
[44] R. DeFronzo,et al. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. , 2011, Endocrine reviews.
[45] D. Loo,et al. Biology of human sodium glucose transporters. , 2011, Physiological reviews.
[46] R. Henry,et al. SGLT2 inhibition — a novel strategy for diabetes treatment , 2010, Nature Reviews Drug Discovery.
[47] C. Bailey,et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.
[48] J. Gerich. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications , 2010, Diabetic medicine : a journal of the British Diabetic Association.
[49] Ferhaan Ahmad,et al. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. , 2009, Cardiovascular research.
[50] M. Pfister,et al. Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus , 2009, Clinical pharmacology and therapeutics.
[51] O. Marsenic. Glucose control by the kidney: an emerging target in diabetes. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[52] Grant D. Huang,et al. Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.
[53] S. Schinner. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .
[54] R. Holman,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.
[55] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[56] D. Goff,et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. , 2007, The American journal of cardiology.
[57] Chari D Smith,et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. , 2005, Diabetes.
[58] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[59] H. Taegtmeyer,et al. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. , 2002, Circulation.
[60] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[61] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[62] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[63] C. M. White. A Review of Potential Cardiovascular Uses of Intravenous Glucagon Administration , 1999, Journal of clinical pharmacology.
[64] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[65] T. Ruigrok,et al. The role of the Na+ channel in the accumulation of intracellular Na+ during myocardial ischemia: consequences for post-ischemic recovery. , 1997, Journal of molecular and cellular cardiology.
[66] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[67] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[68] Weder Ab. Sodium metabolism, hypertension, and diabetes. , 1994 .
[69] A. Weder. Sodium metabolism, hypertension, and diabetes. , 1994, The American journal of the medical sciences.
[70] P. Weidmann,et al. Central Role of Sodium in Hypertension in Diabetic Subjects , 1991, Diabetes Care.
[71] R. DeFronzo,et al. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. , 1975, The Journal of clinical investigation.
[72] B. R. Madan,et al. Effect of glucagon on ventricular arrhythmias after coronary artery occlusion and on ventricular automaticity in the dog , 1971, British journal of pharmacology.
[73] G. Diamond,et al. Haemodynamic effects of glucagon during acute myocardial infarction with left ventricular failure in man. , 1971, British heart journal.
[74] K. Hutchison,et al. Haemodynamic effects of glucagon , 1970, British heart journal.